In August 2018 Kos designed, developed, and implemented the Modafinil Patient Screening Program (Modafinil Program) and the Nuvigil® Patient Program (Nuvigil® Program) for Teva Pharma Australia Pty. Ltd. (Teva). It partnered with PharmaPrograms to facilitate the Program through community pharmacies. Modafinil and Nuvigil® (armodafinil) are both listed on the Pharmaceutical Benefits Scheme (PBS). Modafinil and Nuvigil® are two wakefulness-promoting agents for oral administration.